Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 11:12:8379-8386.
doi: 10.2147/CMAR.S224223. eCollection 2020.

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

Rohit K Jain  1 , William Paul Skelton 4th  1 , Jingsong Zhang  1
Affiliations
Review

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

Rohit K Jain et al. Cancer Manag Res. .

Abstract

Enfortumab vedotin (EV) is an antibody-drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that led to the accelerated approval of EV for treating patients with metastatic urothelial cancer. Emerging clinical data on EV-based combinational therapeutic trials for metastatic urothelial cancer were also reviewed.

Keywords: antibody-drug conjugate; enfortumab vedotin; urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

Rohit K Jain has received honoraria from DAVA Oncology, Advisory board for Pfizer and speaker program from Astellas Pharma Inc/ Seattle Genetics. Jingsong Zhang has received honoraria for advisory boards and speaker programs from AstraZeneca, Merck, Seattle Genetics and Astellas Pharma Inc. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590 - DOI - PubMed
    1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15. - PMC - PubMed
    1. National Comprehensive Cancer Network. Bladder cancer (Version 3.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder_blocks.pdf. Accessed March30, 2020.
    1. Jain RK, Snyders T, Nandgoapal L, Garje R, Zakharia Y, Gupta S. Immunotherapy advances in urothelial carcinoma. Curr Treat Options Oncol. 2018;19(12):79. doi:10.1007/s11864-018-0598-x - DOI - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683 - DOI - PMC - PubMed